Home/Filings/4/0001437749-22-021742
4//SEC Filing

Witter Malcolm G 4

Accession 0001437749-22-021742

CIK 0000810509other

Filed

Aug 31, 8:00 PM ET

Accepted

Sep 1, 9:46 PM ET

Size

9.6 KB

Accession

0001437749-22-021742

Insider Transaction Report

Form 4
Period: 2022-08-30
Transactions
  • Purchase

    Series I Convertible Preferred Stock

    2022-08-30+115115 total
    Exercise: $0.45From: 2022-08-30Common Stock (255,530 underlying)
  • Award

    Common Stock

    2022-08-31+2,500158,888 total
  • Purchase

    Warrant to Purchase Common Stock

    2022-08-30+115115 total
    Exercise: $0.50From: 2022-08-30Exp: 2027-08-30Common Stock (255,530 underlying)
Footnotes (4)
  • [F1]Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.
  • [F2]Issuance deferred at the request of the Reporting Person.
  • [F3]The Reporting Person acquired the Series I Convertible Preferred Stock and Warrants to Purchase Common Stock pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering ("Rights Offering"), as disclosed in the Registration Statement on Form S-1, as amended, and Prospectus Supplement No. 1 filed by the Issuer with the Securities and Exchange Commission. Pursuant to the Rights Offering, the Reporting Person purchased units at a subscription price of $1,000 per unit, with each unit consisting of one (1) share of Series I Convertible Preferred Stock and one (1) Warrant to Purchase 2,222 shares of Common Stock.
  • [F4]Series I Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.

Issuer

NAVIDEA BIOPHARMACEUTICALS, INC.

CIK 0000810509

Entity typeother

Related Parties

1
  • filerCIK 0001838283

Filing Metadata

Form type
4
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 9:46 PM ET
Size
9.6 KB